Who
Rajiv Patni
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Septerna; Director, BioXcel Therapeutics; Director, Quince Therapeutics; EVP, Chief R&D Officer, Reata Pharmaceuticals; EVP, Cmo, Portola Pharmaceuticals; Chief Medical Officer, Adamas Pharmaceuticals; Chief Development Officer, Ocera Therapeutics.
In numbers
- Trades disclosed
- 32
- Buys
- 1
- Sells
- 3
- Bought
- $20K
- Sold
- $64K
- Companies
- 7
- Companies where not an officer
- 2
- First trade
- 2 Sep 2014
- Last trade
- 8 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 10 Sep 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 15 Jan 2025filed 16 Jan 2025 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 15 Feb 2024filed 15 Feb 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,000 at $0.00 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —90,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticals | SEC FORM 4 Code D | —45,000 | filing |
| 12 Jun 2023filed 14 Jun 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 12 Jun 2023filed 14 Jun 2023 | Reata Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 2 Jul 2020filed 2 Jul 2020 | Portola Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $986K125,000 at $7.89 | filing |
| 2 Jul 2020filed 2 Jul 2020 | Portola Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 28 Feb 2020filed 3 Mar 2020 | Portola Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 28 Feb 2020filed 3 Mar 2020 | Portola Pharmaceuticals | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 8 Apr 2019filed 10 Apr 2019 | Adamas Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 8 Apr 2019filed 10 Apr 2019 | Adamas Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Mar 2019filed 21 Mar 2019 | Adamas Pharmaceuticals | SEC FORM 4 Sold | $19K2,374 at $8.00 | filing |
| 21 Mar 2018filed 22 Mar 2018 | Adamas Pharmaceuticals | SEC FORM 4 Sold | $32K1,252 at $25.94 | filing |
News
No headline names them, or the companies they trade most, lately.